1261225-48-2

Usage

Uses

Used in Pharmaceutical Research:
[3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester is utilized as a research compound for exploring its biological activity. Its unique structure may contribute to the development of new drugs or therapeutic agents, particularly in areas where its specific functional groups can interact with biological targets.
Used in Chemical Synthesis:
In the field of chemical synthesis, [3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester serves as a synthetic intermediate or building block. Its presence in complex molecular structures can be leveraged to create novel compounds with specific properties, potentially leading to advancements in various chemical and material sciences.
Used in Drug Development:
[3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester is employed as a precursor in the synthesis of pharmaceuticals. Its ability to be modified and incorporated into larger molecules makes it a valuable tool in the design and creation of new drugs with improved efficacy and selectivity.
Used in Environmental and Health Safety Protocols:
Given the potential hazards associated with [3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester, it is also used in the development of safety protocols and guidelines for handling and storage. This ensures that researchers and workers are protected from potential health risks, and the environment is safeguarded from contamination.

Upstream product

• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 222530-39-4 (1R,3S)-3-(tert-butoxycarbonylamino)aminocyclohexanecarboxylic acid 
• 100-51-6 benzyl alcohol 
• 347186-01-0 N-(3-aminocyclohexyl)(t-butoxy)carboxamide 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1259278-17-5 tert-butyl N-[(1R,3S)-3-aminocyclohexyl]carbamate 

Relevant academic research and scientific papers

CYCLOALKANE-1,3-DIAMINE DERIVATIVE

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

HETEROCYCLIC INDOLES FOR USE IN INFLUENZA VIRUS INFECTION

The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS

Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:wherein R1, R2, R3, and L, A, and Ra are defined herein.